Education Library

Aditya Bharadwaj, MD, walks through the first PROTECT IV case enrolled at Loma Linda University Health Care in California.

Babar Basir, MD, discusses how hemodynamics can help clinicians decide whether to use mechanical circulatory support (MCS) in patients undergoing high-risk PCI.

Mihas Kodenchery, MD, and Laura Rodriguez, NP, discuss the low mortality and low complication rates in their high-volume high-risk PCI practice.
 

William O’Neill, MD, discusses the current state of mechanical circulatory support for AMI cardiogenic shock.
 

Amir Kaki, MD, describes best practices and practical considerations for optimizing care of patients with AMI cardiogenic shock prior to leaving the cath lab.

Bobby Yeh, MD, discusses how real-world evidence factors into treatment decisions made every day in clinical practice.

Arman Kilic, MD, discusses his experiences with collaboration between interventional cardiology and cardiac surgery, particularly regarding Impella 5.5® with SmartAssist® and ECpella.

Navin Kapur, MD, discusses the latest science underlying reperfusion and unloading and how it led to the STEMI-DTU pilot and pivotal trials.

Kate Kearney, MD, discusses studies and strategies for revascularization in heart failure with reduced ejection fraction.

Adam DeVore, MD, reviews data on evaluating patients with heart failure for CAD and discusses opportunities to improve assessment rates for CAD in these patients.

Gregg Stone, MD, presents the newly underway PROTECT IV randomized controlled transcatheter heart failure therapy trial at THT 2022.

Mario Iannaccone, MD, discusses his meta-analysis data supporting pre-PCI placement of Impella® for AMI cardiogenic shock.

A bicarbonate-based purge solution for Impella® may be a viable alternative to heparin-based purge solution in patients who are heparin-intolerant and when heparin is contraindicated.

A heart team approach and hemodynamic assessment led to timely and effective use of Impella 5.5 with SmartAssist for this patient with PCCS.

Claudius Mahr, DO, discusses outcome differences between patients with acute de novo cardiogenic shock and patients with chronic heart failure deteriorating to shock.